Encouraging Results Seen in Patients with Heavily Pre-Treated Low-Grade Serous Ovarian-Recording

Video Transcription

Video Summary

Dr. Rachel Grisham presented the interim results of the RAMP-201 trial at the International Gynecologic Cancer Society meeting. The trial investigated the safety and efficacy of avutimetinib and defactinib in patients with recurrent low-grade serous ovarian cancer. The study enrolled patients with measurable recurrent low-grade serous ovarian cancer who had previously received platinum-based chemotherapy. The initial results showed unprecedented response rates for the combination of avutimetinib and defactinib, with a 45% response rate for the overall population. The combination was found to be efficacious and safe, even in heavily pretreated patients. Dr. Grisham discussed the sequencing of treatment for these patients, generally preferring clinical trial enrollment as the first choice for second-line therapy. She also emphasized the tolerability of the combination therapy, with patients given regular breaks to allow for recovery from adverse events. Dr. Grisham mentioned the ongoing RAMP-301 trial, a randomized phase III study, which is set to open later this year and will evaluate the combination therapy against physician's choice of chemotherapy or endocrine therapy.

Asset Subtitle

Listen to Dr. Rachel Grisham and Dr. Wendel Naumann discuss results from Dr. Grisham's IGCS 2023 late-breaking presentation from Seoul.

Keywords

Dr. Rachel Grisham

RAMP-201 trial

avutimetinib

defactinib

recurrent low-grade serous ovarian cancer